Quick Links

Our Global Community

Local or global—RAPS has you covered with offices in Washington, DC, Shanghai and Singapore. There are RAPS chapters in Canada, Israel, Switzerland, Taiwan and throughout the United States, and local networks in Australia, Belgium, Brazil, Germany, India, Mexico, The Netherlands, Poland and Singapore.

Quick Links

Featured Article

Over the past two decades, the US Food and Drug Administration’s (FDA’s) Center for Drug and Evaluation and Research (CDER) has been developing new, expedited pathways to help bring innovative medical products to market more efficiently. These pathways include fast track designation, accelerated approval, priority review and, more recently, breakthrough therapy. Through these expedited pathways, some products have been approved with fewer clinical data than traditionally are required.

Latest News

In 2014, Japan's regulator, the Pharmaceuticals and Medical Devices Agency (PMDA) edged out the US Food and Drug Administration (FDA) as the world's fastest regulator, with a median approval time of 306 days for new active substances (NASs).

Attending RAPS' Regulatory Convergence conference is an investment in your job, your career and your regulatory knowledge. To get the most out of it, you will want to think a little bit about how best to spend your precious time.

Regulatory Focus is pleased to team with Tarius, a regulatory information services provider, to routinely offer insight about upcoming FDA Scientific Advisory Committee (SAC) meetings for CDER, CBER, and the Office of the Commissioner.

The issue of drug shortages may have largely fallen off the media's radar, but it hasn't stopped being a problem for consumers. Now, in a letter to the US Food and Drug Administration (FDA), Rep. C.W. Bill Young (R-FL) has called on Commissioner Margaret Hamburg to evaluate several new ideas that could act to mitigate or eliminate the shortage crisis.

Background

Drug shortages emerged as a major issue in 2011 and 2012, with many generic sterile injectable drugs experiencing supply shortages. Investigations into the matter brought to light a number of reasons for the shortages, including:

asking manufacturers to notify FDA of any impending supply problems or disruptions

working one-on-one with manufacturers experiencing problems

approving novel manufacturing agreements for some facilities to allow them to release some products for further processing or quality checks-a significant deviation from the usual quality-by-design parameters of current good manufacturing practices (CGMP).

But more remains to be done. Under the FDA Safety and Innovation Act (FDASIA), FDA is charged with formulating a strategic plan on drug shortages (Title X, Section 506D of FDASIA).

That strategic plan is to include ways to "improve interagency and intra-agency coordination, communication and decision making," and mandates that FDA consider the possibility of drug shortages when conducting any regulatory action against a manufacturer. The effects of drug shortages on clinical trials, the possibility of establishing a "qualified manufacturing partner program," and communication plans will also be considered.

Such a "qualified manufacturing partner program" would potentially allow a third-party manufacturer to produce drugs in short supply so long as they have the "capability and capacity" to supply those products. FDA is also set to examine whether incentives are necessary to allow qualified manufacturers to participate in the program.

The report is due "as soon as practicable."

Same Old Problem Prompts New Ideas

In the meantime-and despite FDA's reported progress in reducing the impact of them-drug shortages persist, something not lost on Young.

In a letter to Hamburg on 25 September 2013, Young said he remained concerned about the effects of shortages, which have tripled over the last five years. "I realize this is a very complex problem that cannot be solved overnight," he conceded, noting the various initiatives underway at FDA to look at the problem.

Young asked that FDA study five possible approaches to abating drug shortages:

Could FDA link new drug patents with a commitment to new or continued production of generic or low-cost drugs deemed by FDA to be "critical?"

Would FDA be willing to develop or require real-time monitoring for generic drug volume utilization versus manufacturing production volume to determine if adequate production levels are met?

Could FDA incentivize production or arrange for importation of similar products if generic drugs begin to experience a shortage?

Could FDA be required to remove regulatory barriers that impact the importation of "safe substitute products" and establish a national stockpile of drugs otherwise in short supply?

What would the impact be if FDA stockpiled drugs known to experience chronic supply shortages? How much supply should be permitted?

Get important news and events in regulatory.

Most Viewed News Articles

Monday, the US Food and Drug Administration (FDA) released a draft guidance detailing how it plans to use quality metrics to improve its ability to conduct risk-based inspections and predict or mitigate potential drug shortages. View More